

10 September 2025

ASX Announcement

Firebrick receives \$250,000 R&D Tax Incentive

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has received an RDTI (R&D Tax Incentive) payment of \$250,000 for eligible R&D expenditure incurred in 2024/25.

The incentive payment related to \$576,000 in reported R&D costs in the FY25 year, associated with the Company's further development of Nasodine as a broad spectrum antimicrobial agent and other new product development.

"We welcome the valuable injection of non-dilutive funds from the R&D tax incentive" said Dr Peter Molloy, Executive Director of Firebrick Pharma.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com